Icon

DAKLINZA (nda206843)- (EQ 30MG BASE,EQ 60MG BASE,EQ 90MG BASE)

DACLATASVIR DIHYDROCHLORIDE BRISTOL-MYERS SQUIBB
EQ 30MG BASE,EQ 60MG BASE,EQ 90MG BASE
No No
2031-Jun-13 2020-Jul-24
None None
None No
DAKLINZA is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 30MG BASE ** ** - - -
EQ 60MG BASE ** ** - - -
EQ 90MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.